U.S. COVID-19 Deaths Top a Quarter Million
COVID-19 cases on the rise in all but one state
Predictors of Severe Disease ID’d in Children With SARS-CoV-2
Obesity and hypoxia on admission predictive of severe respiratory disease; children with MIS-C more likely to be non-Hispanic Black
COVID-19-Related Job Insecurity Tied to Anxiety, Depression
Survey of nearly 5,000 young adults reveals link between job insecurity and self-reported anxiety, depression
Major U.S. Medical Groups Urge Trump to Work With Biden on Fighting COVID-19
In letter from three medical associations, the president is urged ‘to share critical data and information as soon as possible’
FDA Approves First Rapid COVID-19 Test for Home Use
Simple nasal swab test requires prescription; people younger than 14 cannot perform the test on themselves
Pandemic Affecting Young People’s Mental Health
Self-reported symptoms of depression, thoughts of suicide much higher than historical norms
Fluvoxamine Linked to Reduction in Clinical Deterioration in COVID-19
Findings seen among adult outpatients with SARS-CoV-2 with oxygen saturation of 92 percent or greater
Ebola Outbreak in Democratic Republic of the Congo Declared Over
Wednesday marks 42 days, or two incubation periods, since the last survivor tested negative for the virus
U.S. FDA Reaffirms Commitment to COVID-19 Vaccine Transparency
While Emergency Use Authorizations (EUA) have received increased attention during the COVID-19 public health emergency, they are not a new tool to the US Food and Drug Administration (FDA).
The Commissioner of FDA Stephen M. Hahn M.D., took a moment on November 17, 2020, to reaffirm FDA’s commitment to transparency around the EUA process and share some updates on our plan to provide more information about FDA’s decisions to issue, revise or revoke EUAs for vaccines.